Dual Chamber ICDs Show No Benefit Over Single-Chamber ICDs In Primary Prevention
This article was originally published in The Gray Sheet
Results of a study published in the May 15 issue of the Journal of the American Medical Association found that dual-chamber implantable cardioverter defibrillators were associated with more complications than single-chamber devices in primary-prevention ICD patients with similar rates of death and hospital readmissions.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.